• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

    4/29/26 8:35:00 AM ET
    $BLTE
    $HCM
    $LOT
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLTE alert in real time by email

    NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference ("dbVIC") held April 28th are now available for online viewing.

    VIEW PRESENTATIONS HERE

    The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section.

    April 28th Company Presentations

    • Lotus Technology Inc. (NASDAQ:LOT)
    • Viomi Technology Co., Ltd (NASDAQ:VIOT)
    • Belite Bio, Inc (NASDAQ:BLTE)
    • First Pacific Company Ltd ((HKEX: 142, OTC:FPAFY)
    • HUTCHMED (China) Limited (AIM: HCM, NASDAQ:HCM, and HKEX:13)
    • HEINEKEN N.V. (OTCQX:HEINY, Euronext Amsterdam: HEIA)) 
    • Yiren Digital Ltd. (NYSE:YRD)
    • Carrefour S.A. (PARIS:CA, OTC:CRRFY) 
    • Radiopharm Theranostics Ltd. (NASDAQ:RADX, ASX: RAD)) 
    • WeRide (NASDAQ:WRD, HKEX: 0800))

    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, media@otcmarkets.com

    Virtual Investor Conferences Contact:

    Greg Young

    Investor Access

    OTC Markets Group

    T (212) 652-5958 M (917) 847-6541

    greg@otcmarkets.com



    Primary Logo

    Get the next $BLTE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLTE
    $HCM
    $LOT
    $RADX

    CompanyDatePrice TargetRatingAnalyst
    Radiopharm Theranostics Limited
    $RADX
    6/4/2026$6.00Buy
    H.C. Wainwright
    WeRide Inc.
    $WRD
    3/31/2026$11.40Buy
    HSBC Securities
    WeRide Inc.
    $WRD
    3/26/2026$11.00Outperform
    BNP Paribas Exane
    WeRide Inc.
    $WRD
    2/10/2026$17.50Outperform
    Macquarie
    Belite Bio Inc
    $BLTE
    1/26/2026$195.00Buy
    BofA Securities
    Belite Bio Inc
    $BLTE
    1/6/2026$191.00Overweight
    Morgan Stanley
    WeRide Inc.
    $WRD
    1/5/2026$13.00Outperform
    CLSA
    Belite Bio Inc
    $BLTE
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    More analyst ratings

    $BLTE
    $HCM
    $LOT
    $RADX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    WeRide to Report Second Quarter and First Half 2026 Financial Results on Wednesday, August 12, 2026

    NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- WeRide Inc. ("WeRide" or the "Company") (NASDAQ:WRD, HKEX: 0800)), a global leader in autonomous driving technology, today announced that it will release its unaudited financial results for the second quarter 2026 and unaudited interim results for the first half of 2026 on Wednesday, August 12, 2026, before the open of the U.S. markets. The Company’s management will host an earnings conference call at 8:00 A.M. U.S. Eastern Time on August 12, 2026 or 8:00 P.M. Hong Kong Time on the same day to discuss the results. Details for the conference call are as follows: Event Title: WeRide Inc. Second Quarter and First Half 2026 Earnings Call English R

    7/22/26 7:40:00 AM ET
    $WRD
    EDP Services
    Technology

    Radiopharm Theranostics Achieves Confirmed Durable Partial Response in Ongoing Phase 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy

    First RECIST-confirmed durable Partial Response at current highest dose level #3 (90mCi) with the patient remaining progression free beyond seven months Second patient dosed remains progression free on treatment with RAD204 with early tumor shrinkage observed after first treatment RAD204 is generally well-tolerated with no dose-limiting toxicities observed in any of the dosing cohorts thus far SYDNEY and MALVERN, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, NASDAQ:RADX, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced

    7/22/26 7:05:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Radiopharm Theranostics Announces Positive Phase 2b Trial Results of RAD 101 for Diagnosis of Brain Metastases

    RAD101 PET demonstrated 93% concordance with MRI across all evaluable lesions, meeting the trial's primary endpoint. 14 patients with available data from six-month follow-up and biopsy show preliminary 86% (12/14) Sensitivity (secondary objective). Specificity data will be available in Q4 2026. The Company plans to advance RAD101 into a U.S. Phase 3 pivotal trial in Q4 2026 The imaging Brain Metastases total addressable market is ~$600+m for which there is no currently approved PET product SYDNEY, July 22, 2026 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiop

    7/22/26 7:00:00 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $HCM
    $LOT
    $RADX
    SEC Filings

    View All

    SEC Form 6-K filed by WeRide Inc.

    6-K - WeRide Inc. (0001867729) (Filer)

    7/22/26 8:19:21 AM ET
    $WRD
    EDP Services
    Technology

    SEC Form 6-K filed by Radiopharm Theranostics Limited

    6-K - Radiopharm Theranostics Ltd (0001949257) (Filer)

    7/22/26 7:00:01 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by WeRide Inc.

    6-K - WeRide Inc. (0001867729) (Filer)

    7/13/26 9:11:56 AM ET
    $WRD
    EDP Services
    Technology

    $BLTE
    $HCM
    $LOT
    $RADX
    Leadership Updates

    Live Leadership Updates

    View All

    Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update

    Initiated a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant for the treatment of Stargardt disease type 1 (STGD1); submission expected to be completed in the second quarter of 2026Commercialization preparation for STGD1 underway; hiring of all key commercial leadership positions completed Cash and cash equivalents, U.S. treasury bills and notes: $798.6 million as of March 31, 2026Conference call and webcast on Wednesday, May 20, 2026, at 4:30 p.m. ET SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE) ("Belite Bio®" or the "Company"), a clinical-stage drug development company focused on advancing nov

    5/20/26 6:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    LOTUS Appoints Piano Master Lang Lang as Friend of the Brand

    NEW YORK, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lotus Technology Inc. ("Lotus Tech" or the "Company") (NASDAQ:LOT), a leading global intelligent and luxury mobility provider, today updated that LOTUS announced world-renowned pianist Lang Lang as its Friend of the Brand, marking a new partnership built on a shared pursuit of precision, performance, and excellence. Recognized globally for his extraordinary technique and expressive artistry, Lang Lang has brought classical music to audiences across cultures and generations. His dedication to mastery through discipline and refinement closely mirrors LOTUS's engineering philosophy, where every detail is shaped to deliver pure driving performance.

    2/6/26 8:30:00 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    Viomi Technology Co., Ltd Appoints Malaysian Pop Star Shila Amzah as Brand Ambassador and Announces New AI Water Purifier Launch in Malaysia

    GUANGZHOU, China, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced the appointment of renowned Malaysian singer Ms. Shila Amzah as its brand ambassador in Malaysia. Ms. Amzah will join Viomi for a product launch event in Malaysia on October 30, where the Company will unveil its new AI water purifier, INNO, designed to bring a smarter and safer drinking water lifestyle to local households. Mr. Xiaoping Chen, Founder and CEO of Viomi, commented: "We are thrilled to welcome Ms. Shila Amzah as our brand ambassador in Malaysia. Together, at our upcoming product

    10/20/25 9:00:28 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    $BLTE
    $HCM
    $LOT
    $RADX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Radiopharm Theranostics with a new price target

    H.C. Wainwright initiated coverage of Radiopharm Theranostics with a rating of Buy and set a new price target of $6.00

    6/4/26 8:45:49 AM ET
    $RADX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HSBC Securities initiated coverage on WeRide with a new price target

    HSBC Securities initiated coverage of WeRide with a rating of Buy and set a new price target of $11.40

    3/31/26 10:45:27 AM ET
    $WRD
    EDP Services
    Technology

    BNP Paribas Exane initiated coverage on WeRide with a new price target

    BNP Paribas Exane initiated coverage of WeRide with a rating of Outperform and set a new price target of $11.00

    3/26/26 8:52:50 AM ET
    $WRD
    EDP Services
    Technology

    $BLTE
    $HCM
    $LOT
    $RADX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Scholl Hendrik Peter sold $1,452,435 worth of American depositary share (10,000 units at $145.24) (SEC Form 4)

    4 - BELITE BIO, INC (0001889109) (Issuer)

    6/22/26 6:05:45 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Scholl Hendrik Peter sold $1,405,729 worth of American depositary share (10,000 units at $140.57) (SEC Form 4)

    4 - BELITE BIO, INC (0001889109) (Issuer)

    6/17/26 6:03:33 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman and CEO Tang Ning acquired 81,176,519 units of Ordinary Shares (SEC Form 4)

    4 - Yiren Digital Ltd. (0001631761) (Issuer)

    6/8/26 8:12:59 PM ET
    $YRD
    Finance: Consumer Services
    Finance

    $BLTE
    $HCM
    $LOT
    $RADX
    Financials

    Live finance-specific insights

    View All

    WeRide to Report Second Quarter and First Half 2026 Financial Results on Wednesday, August 12, 2026

    NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- WeRide Inc. ("WeRide" or the "Company") (NASDAQ:WRD, HKEX: 0800)), a global leader in autonomous driving technology, today announced that it will release its unaudited financial results for the second quarter 2026 and unaudited interim results for the first half of 2026 on Wednesday, August 12, 2026, before the open of the U.S. markets. The Company’s management will host an earnings conference call at 8:00 A.M. U.S. Eastern Time on August 12, 2026 or 8:00 P.M. Hong Kong Time on the same day to discuss the results. Details for the conference call are as follows: Event Title: WeRide Inc. Second Quarter and First Half 2026 Earnings Call English R

    7/22/26 7:40:00 AM ET
    $WRD
    EDP Services
    Technology

    Yiren Digital Reports First Quarter 2026 Unaudited Financial Results

    BEIJING, June 25, 2026 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and global markets, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter 2026 Operational ResultsCredit Solution BusinessTotal loans facilitated in the first quarter of 2026 were RMB8.9 billion (US$1.3 billion), representing a decrease of 26% compared to RMB12.0 billion in the fourth quarter of 2025, and a decrease of 42% compared to RMB15.2 billion in the same period of 2025.Number of borrowers served in the fi

    6/25/26 7:00:00 AM ET
    $YRD
    Finance: Consumer Services
    Finance

    Yiren Digital to Report First Quarter 2026 Financial Results on June 25, 2026

    BEIJING, June 17, 2026 /PRNewswire/ -- Yiren Digital Ltd. (NYSE:YRD) ("Yiren Digital" or the "Company"), a leading fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and global markets, today announced that it plans to release its unaudited financial results for the first quarter ended March 31, 2026 before U.S. market opens on Thursday, June 25, 2026. Yiren Digital's management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on June 25, 2026 (or 8:00 p.m. Beijing/Hong Kong Time on June 25, 2026).Participants who wish to join the call should register online in advance of the conference at: https://dpregist

    6/17/26 5:00:00 AM ET
    $YRD
    Finance: Consumer Services
    Finance

    $BLTE
    $HCM
    $LOT
    $RADX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Viomi Technology Co. Ltd

    SC 13G/A - Viomi Technology Co., Ltd (0001742770) (Subject)

    11/12/24 6:35:53 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    SEC Form SC 13G filed by Lotus Technology Inc.

    SC 13G - Lotus Technology Inc. (0001962746) (Subject)

    11/12/24 6:07:58 AM ET
    $LOT
    Auto Manufacturing
    Industrials

    SEC Form SC 13G filed by Lotus Technology Inc.

    SC 13G - Lotus Technology Inc. (0001962746) (Subject)

    11/8/24 6:04:35 AM ET
    $LOT
    Auto Manufacturing
    Industrials